Core Insights - Femasys Inc. has announced a strategic distribution partnership with OR Consulting to launch its product portfolio in Switzerland, which includes FemBloc Permanent Birth Control and FemaSeed Intratubal Insemination, as part of its European expansion strategy [1][2] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally, with a patent-protected portfolio of therapeutic and diagnostic products [3] - The company's fertility portfolio includes FemaSeed, which is over twice as effective as traditional IUI, and FemVue, a companion diagnostic for fallopian tube assessment [3] Product Details - FemBloc is the first non-surgical, in-office alternative to surgical sterilization, receiving full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025 [4] - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success, demonstrating compelling effectiveness and high satisfaction among patients and practitioners [4] Market Strategy - The partnership with OR Consulting is aimed at strengthening Femasys' European commercial platform and expanding access to its innovative technologies through experienced regional partners [2] - The ongoing launches in Spain and France, along with the entry into Switzerland, reflect the company's disciplined approach to building a multi-country footprint [2]

Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, UT. About Enovis Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solutions that enhance patient outcomes an ...

Core Insights - iotaMotion has received FDA 510(k) clearance for its iotaSOFT Insertion System, now approved for use in pediatric patients aged four years and older, enhancing access to robotic-assisted cochlear implantation for school-aged children [1][2] Company Overview - OrthoPediatrics Corp. focuses exclusively on pediatric orthopedics and has developed a comprehensive product offering to improve the lives of children with orthopedic conditions, marketing over 85 products across three major categories: trauma and deformity, scoliosis, and sports medicine [4] - The company aims to expand its impact in pediatric care by leveraging advanced technologies like the iotaSOFT system, which aligns with its mission to address unmet pediatric needs [3] Partnership and Technology - The partnership with iotaMotion aims to enhance cochlear implant surgery through the iotaSOFT system, which is the first FDA-authorized open platform robotic-assisted technology designed to reduce surgical variability [2] - Cincinnati Children's Hospital has become the first dedicated pediatric center to adopt the iotaSOFT Insertion System, joining over 35 leading cochlear implant centers in the U.S. [3] Industry Impact - The introduction of robotic-assisted cochlear implantation is seen as a significant advancement in the cochlear implant program, reflecting a commitment to integrating innovations that benefit patient care [4]

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: STAAR Surgical has named Warren Foust and Deborah Andrews as interim co-CEOs as it seeks a permanent leader, the company said Monday. Stephen Farrell stepped down as CEO at the end of January, leaving the company after an activist investor successfully lobbied for STAAR shareholders to reject Alcon’s $1.6 billion buyout offer. Foust and Andrews, STAAR ...

然而，技术的发展需要价值罗盘。我们也应清醒地认识到：再精密的代码也替代不了医学的温度，再高 效的算法也计算不出生命的重量。技术可以指数级进化，但制度必须跟进。医疗领域涉及决策模型须通 过伦理可解释性审计，要引入算法追溯机制，用区块链固化训练数据与决策路径，可追溯、可量化。 医疗健康从来都是人类最大的公约数，人工智能作为技术演进洪流中最澎湃的动能，正以前所未有的速 度和深度重构医疗服务模式和医学研究方法。上海人工智能研究院建设并发挥高端专业智库能力，这本 《2025 AI+医疗健康产业应用图谱》，全景式呈现了在医疗健康领域中人工智能技术的关键技术栈和代 表性应用案例，洞察AI+医疗健康产业未来的发展方向和趋势。希望让政策制定者看见乘数效应，让从 业者看见技术锚点，让医生看见指南落地，让公众看见自己被看见。 "医学是一门不确定的科学和充满温度的艺术。"希望这本图谱能够照亮技术，也照亮人心；看见产业， 也看见温度。 上海人工智能研究院院长宋海涛 在这场引发医疗服务模式的范式变革中，具有颠覆性的变量来自具身智能。术前，虚拟分诊护士能够综 合症状、可穿戴数据与电子病历，把患者精准分流、缩短黄金救治时间；术中，手术导航机 ...

Core Viewpoint - Canopy Growth Corporation (CGC) is expected to report its third-quarter fiscal 2026 results on February 6, with a projected revenue of $50.6 million and a loss per share of 3 cents, indicating a significant increase in losses compared to the previous year [1][2][9]. Financial Performance - In the last reported quarter, CGC posted a loss per share of 1 cent, which was 90.9% better than the Zacks Consensus Estimate [1]. - The Zacks Consensus Estimate for fiscal third-quarter revenues is $50.6 million, reflecting a decrease of 5.3% from the same quarter last year [2]. - The loss per share estimate for the fiscal third quarter has remained constant at 3 cents over the past 30 days [3]. Market Segments - Canopy's cannabis operations encompass both recreational and medical markets, with previous quarter results showing growth in cannabis revenues driven by adult-use and medical cannabis segments in Canada [4]. - Adult-use revenue growth in Canada may have been supported by strong consumer demand for infused pre-roll joints (PRJ) and the launch of All-In-One (AIO) vape products [5]. - Medical cannabis sales in Canada likely benefited from increased insured patient enrollments, larger average order sizes, and an expanded product portfolio under the Spectrum Therapeutics brand [5]. International Operations - International cannabis revenues are under pressure due to ongoing supply-chain and execution challenges in Europe, similar to trends from the previous quarter [6]. - The company has initiated a turnaround strategy focusing on operational oversight and transitioning back to internally produced Canadian GMP flower, which appears to be positively influencing performance [6]. Strategic Initiatives - During the quarter, CGC launched several strategic initiatives, including the Claybourne Gassers range of AIO vaporizers and expanded the Spectrum Therapeutics portfolio in Australia with new softgel capsule offerings [8]. - The company also entered into an agreement to acquire all issued and outstanding common shares of MTL Cannabis Corp., indicating a focus on portfolio optimization and market consolidation [10].

Core Viewpoint - The 2025 Central Economic Work Conference emphasizes the expansion of international technology innovation centers in Beijing (Jing-Jin-Ji), Shanghai (Yangtze River Delta), and the Guangdong-Hong Kong-Macao Greater Bay Area, aiming to enhance regional innovation capabilities and address existing bottlenecks in innovation development [1][9][20]. Group 1: Beijing and Shanghai's Current Status - Beijing has maintained its position as the top global research city for nine consecutive years, with R&D investment intensity stable at around 6% [1]. - Shanghai has established 20 major technological infrastructures, with the total market value of listed companies on the Sci-Tech Innovation Board ranking first in the country [1]. - The expansion to Jing-Jin-Ji and the Yangtze River Delta aims to overcome innovation development bottlenecks and release new momentum for growth [1][9]. Group 2: Collaborative Development in Jing-Jin-Ji - The cross-regional division of labor in Jing-Jin-Ji has developed, with R&D in Beijing, manufacturing in Tianjin, and assembly in Hebei [5][7]. - During the 14th Five-Year Plan, the technology contract transaction amount from Beijing to Tianjin and Hebei exceeded 320 billion yuan, with an annual growth rate of 23%, indicating a significant increase compared to the previous five-year period [7]. - The collaborative development strategy has allowed companies like Beijing Jingdiao Group to thrive by focusing on R&D while leveraging manufacturing capabilities in Tianjin and assembly in Hebei [5][12]. Group 3: Challenges and Solutions in Regional Cooperation - Despite the progress, challenges remain in the collaborative framework, such as insufficient industrial coordination and barriers to the free flow of talent and resources among the three regions [10][12]. - The establishment of the Xiong'an New Area's Zhongguancun Science Park exemplifies efforts to break down administrative barriers and enhance cross-regional collaboration [14][16]. - The Xiong'an initiative has attracted over 260 enterprises, with 65% from Beijing, creating specialized industrial chains and generating over 1,200 new intellectual property rights [16]. Group 4: Long-term Vision for the Yangtze River Delta - The Yangtze River Delta has established a joint mechanism for cross-regional collaboration, funding over 100 joint projects with a total investment exceeding 1.7 billion yuan since 2022 [9][18]. - The National Major Science and Technology Infrastructure for Translational Medicine aims to create a shared resource platform to facilitate innovation and reduce R&D costs for companies in the region [18][19]. - The "Yangtze River Delta Technology Resource Sharing Service Platform" has gathered over 56,000 large scientific instruments and facilitated nearly 12,000 services for enterprises, demonstrating the effectiveness of resource sharing [19]. Group 5: Future Directions and Goals - The strategic expansion aims to transform the existing collaborative foundation into a competitive advantage on the international stage, enhancing the innovation capabilities of both Jing-Jin-Ji and the Yangtze River Delta [9][20]. - By 2030, the goal is for Beijing to become a world-class source of technological innovation, while Shanghai aims to significantly enhance its position and influence in the global innovation network [20][22]. - The overall vision is to create a more integrated and efficient innovation ecosystem across these regions, fostering a new model of development that emphasizes collaboration and resource sharing [22].

Core Viewpoint - The agreement between CFFM and Pulsenmore marks a significant advancement in prenatal care, enabling remote monitoring through home ultrasound services, which enhances patient access and reduces unnecessary visits to diagnostic centers [1][5]. Company Overview - Pulsenmore is focused on transforming maternal health with home-use ultrasound technology that connects mothers and healthcare providers remotely, aiming to improve access and continuity of prenatal care [6]. - CFFM is a prenatal diagnostic center in California that specializes in high-risk pregnancies, managing approximately 1,500 pregnancies annually across two locations in the Los Angeles area [3]. Technological Innovation - Pulsenmore's ultrasound system is designed to empower expectant mothers by providing safe, guided access to ultrasound imaging from home or work, while maintaining close clinician involvement throughout the process [4]. - The collaboration with CFFM will facilitate a remote pregnancy monitoring model that prioritizes patient needs, demonstrating the potential of home-based ultrasound as a routine part of medical care [6]. Market Potential - The agreement with CFFM represents Pulsenmore's first commercial venture in the United States, following recent FDA clearance, and is seen as a crucial step in the company's strategic plan to tap into the U.S. market, which holds significant clinical and business opportunities [5].

YOKNEAM, Israel, Feb. 2, 2026 /PRNewswire/ -- InMode Ltd. (NASDAQ: INMD), a leading global provider of innovative medical technologies ("InMode" or the "Company"), today issued the following statement: The Company is aware of recent market speculation and rumors, including reports relating to the publicly announced non-binding proposal by Steel Partners Holdings L.P. to acquire 51% of the Company's outstanding shares and recent statements attributed to the Company's Chief Executive Officer. Without derogat ...

Company Overview - PROCEPT BioRobotics is a healthcare technology company specializing in robotic surgical systems for minimally invasive urology procedures, particularly targeting benign prostatic hyperplasia (BPH) treatment [6][9] - The company utilizes proprietary image-guided robotic systems to enhance patient outcomes and hospital efficiency, with a competitive edge stemming from its innovative Aquablation therapy and a growing installed base [6][9] Financial Performance - As of January 26, PROCEPT BioRobotics had a market capitalization of $1.65 billion, with a trailing twelve months (TTM) revenue of $299.91 million and a net income loss of $84.58 million [4] - The company reported a 43% year-over-year revenue increase in the third quarter, amounting to $83.3 million, and a gross margin expansion to 65% [11] - Management provided revenue guidance for 2026, projecting between $410 million and $430 million, indicating potential growth of up to 32% from 2025 levels [11] Recent Transactions - Chicago Capital disclosed a reduction in its stake in PROCEPT BioRobotics by 377,850 shares in the fourth quarter, translating to an estimated transaction value of $12.53 million [2][3] - Following this transaction, Chicago Capital's remaining stake in PROCEPT was valued at $37.47 million, with the position now accounting for 0.93% of its 13F assets, down from 1.38% in the previous quarter [2][3] Stock Performance - As of January 26, PROCEPT BioRobotics shares were priced at $29.61, reflecting a significant decline of 60.4% over the past year, contrasting sharply with the S&P 500's approximate 14% gain during the same period [3][11] - The stock's performance has raised concerns regarding operating losses, high spending, and the pace at which growth can lead to sustainable profitability, as evidenced by an adjusted EBITDA loss of $7.4 million in the quarter [11]